RLMD - NASDAQ
Relmada Therapeutics, Inc.
$6.38
-0.62%Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
At a Glance
Live SnapshotRelmada Therapeutics, Inc. Management Team
Mr. Charles S. Ence CPA, M.B.A.
Chief Accounting & Compliance Officer
Compensation
$983,039
Dr. Sergio Traversa M.B.A., Pharm.D.
Chief Executive Officer & Director
Compensation
$1,800,723
Mr. Maged S. Shenouda M.B.A., R.Ph.
Chief Financial Officer
Compensation
$993,750
Mr. Paul E. Kelly M.B.A.
Chief Operating Officer & Director
Compensation
$872,780
Dr. Richard M. Mangano Ph.D.
Consultant
Dr. Andrew Cutler
Senior Clinical Development Advisor
Ms. Gina DiGuglielmo
Vice President & Head of Clinical Operations
Relmada Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.21M worth of RLMD shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
39.2K
161.36K
0
0.00
+161K
+$161K
6-9 Months
998.5K
2.20M
0
0.00
+2.2M
+$2.20M
9-12 Months
2.8M
1.85M
0
0.00
+1.9M
+$1.85M
Top Buyers
Shenouda Maged
Officer: Chief Financial Officer
$1.55M
Traversa Sergio
Director, Officer: Chief Executive Officer
$1.43M
Ence Chuck
Officer: Cao And Coo
$567K
Kelly Paul Edward
Director, Officer: Chief Operating Officer
$466K
Casamento Charles J
Director
$67K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.21M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
RLMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 11, 2025 | May 23, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | May 24, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 31, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 11, 2022 | May 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 31, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | January 31, 2020 | March 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | January 09, 2019 | February 27, 2019 | 2019 | |
DEF 14A DEF 14A 2017 N/A | December 15, 2017 | December 18, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | December 30, 2016 | January 27, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.